Neurogene (NGNE) Change in Accured Expenses (2013 - 2026)
Neurogene (NGNE) posted Change in Accured Expenses of $359000.0 for Q1 2026, down 73.03% on a QoQ basis from $1.3 million in Q4 2025, and up 116.3% year-over-year from $165976.3 in Q1 2025.
Neurogene (NGNE) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Neurogene's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $359000.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 116.3% year-over-year to $359000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 4457.73% YoY) and the FY2025 annual result came in at $1.7 million, up 160.04% from the prior year.
- Change in Accured Expenses was $359000.0 for Q1 2026 at Neurogene, down from $1.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.6 million in Q3 2024 and bottomed at -$4.9 million in Q1 2024.
- A 5-year average of -$206882.4 and a median of $359000.0 in 2026 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 260.08% — and 2025, when it soared 949.28%.
- Neurogene's Change in Accured Expenses stood at -$1.0 million in 2022, then plunged by 260.08% to -$3.7 million in 2023, then surged by 79.71% to -$743000.0 in 2024, then soared by 279.14% to $1.3 million in 2025, then sank by 73.03% to $359000.0 in 2026.
- Business Quant data shows NGNE's Change in Accured Expenses at $359000.0 in Q1 2026, $1.3 million in Q4 2025, and $365000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -16.74 Mn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | 359,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 359,000.00 |
| Mar 31, 2026 | 359,000.00 |
| Dec 31, 2025 | 1.33 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 365,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 2.17 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | -2.20 Mn |
| Mar 31, 2025 | -2.20 Mn |
| Dec 31, 2024 | -743,000.00 |
| Dec 31, 2024 | -743,000.00 |
| Sep 30, 2024 | 2.64 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 207,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Mar 31, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Dec 31, 2023 | -3.66 Mn |
| Dec 31, 2023 | -3.66 Mn |